Dengue Fever

Infectious Diseases
9
Pipeline Programs
5
Companies
12
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
4
0
3
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
5100%
+ 7 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
6 programs
1
2
3
9vHPV VaccinePhase 3Vaccine1 trial
Tetravalent Dengue VaccinePhase 3Vaccine1 trial
Tetravalent Dengue VaccinePhase 3Vaccine1 trial
TDVPhase 21 trial
Takeda's Tetravalent Dengue Vaccine CandidatePhase 2Vaccine1 trial
+1 more programs
Active Trials
NCT01728792Completed80Est. Nov 2013
NCT03746015Completed30Est. Mar 2021
NCT02425098Completed351Est. Sep 2017
+3 more trials
Sanofi
SanofiPARIS, France
3 programs
1
Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virusPhase 21 trial
Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue VaccineN/AVaccine1 trial
Study of Febrile Illness for Dengue-Endemic Areas in Latin AmericaN/A1 trial
Active Trials
NCT02948933Completed30,000Est. Dec 2022
NCT01293331Completed3,000Est. Apr 2012
NCT01064141Completed210Est. Nov 2012
Atea Pharmaceuticals
1 program
1
AT-752Phase 21 trial
Active Trials
NCT05466240TerminatedEst. Jan 2023
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
1
rDEN4delta30-200,201Phase 11 trial
Active Trials
NCT00270699CompletedEst. Dec 2009
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
ObservationN/A1 trial
Active Trials
NCT01550016Completed7,411Est. Oct 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
TakedaTetravalent Dengue Vaccine
Takeda9vHPV Vaccine
TakedaTetravalent Dengue Vaccine
Atea PharmaceuticalsAT-752
TakedaTDV
TakedaTakeda's Tetravalent Dengue Vaccine Candidate
SanofiLive, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus
TakedaTDV
Allergy TherapeuticsrDEN4delta30-200,201
SanofiCohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine
Heidelberg PharmaObservation
SanofiStudy of Febrile Illness for Dengue-Endemic Areas in Latin America

Clinical Trials (12)

Total enrollment: 42,392 patients across 12 trials

NCT07047521TakedaTetravalent Dengue Vaccine

A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults

Start: Nov 2025Est. completion: Jul 2027496 patients
Phase 3Active Not Recruiting
NCT04313244Takeda9vHPV Vaccine

Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 Years

Start: May 2021Est. completion: Jul 2022614 patients
Phase 3Completed
NCT03771963TakedaTetravalent Dengue Vaccine

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults

Start: Mar 2019Est. completion: Mar 2020200 patients
Phase 3Completed
NCT05466240Atea PharmaceuticalsAT-752

Study of AT-752 in Patients With Dengue Infection

Start: Apr 2022Est. completion: Jan 2023
Phase 2Terminated
NCT03746015TakedaTDV

Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults

Start: Dec 2018Est. completion: Mar 202130 patients
Phase 2Completed
NCT02425098TakedaTakeda's Tetravalent Dengue Vaccine Candidate

Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore

Start: Jun 2015Est. completion: Sep 2017351 patients
Phase 2Completed
NCT01064141SanofiLive, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus

A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines

Start: Jan 2010Est. completion: Nov 2012210 patients
Phase 2Completed
NCT01728792TakedaTDV

Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity

Start: Jan 2013Est. completion: Nov 201380 patients
Phase 1Completed
NCT00270699Allergy TherapeuticsrDEN4delta30-200,201

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy Adults

Start: Jun 2006Est. completion: Dec 2009
Phase 1Completed
NCT02948933SanofiCohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine

Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine

Start: Dec 2016Est. completion: Dec 202230,000 patients
N/ACompleted
NCT01550016Heidelberg PharmaObservation

International Research Consortium on Dengue Risk Assessment, Management, and Surveillance

Start: Oct 2011Est. completion: Oct 20167,411 patients
N/ACompleted
NCT01293331SanofiStudy of Febrile Illness for Dengue-Endemic Areas in Latin America

Study of Febrile Illness for Dengue-Endemic Areas in Latin America

Start: Aug 2010Est. completion: Apr 20123,000 patients
N/ACompleted

Related Jobs in Infectious Diseases

Senior Recruiter

Invivyd
New Haven, CT (Northeast preferred)
5h ago
$120K - $160K/yr

Senior Associate Scientist (contract), Upstream Polysaccharide Process Development

VaxCyte
San Carlos, California, United States
8h ago
$56/hr

Senior Associate Scientist (contract), Polysaccharide Analytical Development

VaxCyte
San Carlos, California, United States
8h ago
$56/hr

Director, Program Management

Metaphore Biotechnologies
Somerville, MA USA
12h ago
$179K - $237K/yr

First Line Sales Leader (Medan)

GSK
Indonesia - Sumatera Utara
Yesterday

General Worker

GSK
Pakistan - Sindh - Karachi
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
5 companies competing in this space

Related Indications

HIV Infections(449)COVID-19(223)Hepatitis C(191)Influenza(173)HIV(138)HIV-1-infection(115)Hepatitis C, Chronic(94)Chronic Hepatitis B(93)Chronic Hepatitis C(91)Covid19(79)